Newsgroup: it.economia.borsa
Titolo: Novità......

Cell Therapeutics, Inc. Announces $82 Million in Convertible Senior Notes 
Offering
Tuesday November 1, 7:43 am ET
Company Concurrently Agrees to Retire $38.4 Million of Old Debt Through 
Equity Exchange
SEATTLE, Nov. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) 
(Nasdaq: CTIC; MTAX) today entered into an agreement to issue $82 million of 
6.75% convertible senior notes ("Notes") due in 2010 only to qualified 
institutional buyers pursuant to Rule 144A under the Securities Act of 1933, 
as amended (the "Notes Agreement").
ADVERTISEMENT
The Notes will bear interest at a rate of 6.75% per annum and will be 
convertible for shares of CTI common stock at the rate of 378.78 shares per 
$1,000 principal amount of Notes, which is equivalent to an initial 
conversion price of approximately $2.63 per share, which is equal to 110% of 
the closing bid price on October 31, 2005. The Notes will rank pari passu in 
right of payment with all existing and future senior indebtedness of CTI, 
and will rank senior in right of payment to CTI's currently outstanding 
convertible notes. Holders of the Notes would also have the right to cause 
CTI to redeem up to 30% of the aggregate principal amount of the Notes (or 
approximately $24.6 million) on a pro rata basis on April 30, 2006, and any 
such redemption would exclude any accrued and unpaid interest. The Notes 
Agreement is expected to close by November 4, 2005, subject to closing 
conditions, including the condition that the prospective investors have not 
withdrawn their commitment to purchase the Notes. CTI cannot provide any 
assurance regarding the amount of Notes to be issued, if any, until the 
Notes Agreement is closed.
CTI also announced today that it has entered into a Conversion and Placement 
Agreement ("CAP Agreement") with two qualified institutional buyers who are 
existing holders (the "CAP Holders") of an aggregate amount of approximately 
$38.38 million of its outstanding 5.75% Convertible Senior Subordinated 
Notes due June 15, 2008 ("5.75% Notes") and 4% Convertible Senior 
Subordinated Notes due July 1, 2010 ("4% Notes"). Pursuant to the terms of 
the CAP Agreement, the CAP Holders have agreed to exercise their right to 
convert their 5.75% Notes and 4% Notes into approximately 3.3 million shares 
of CTI common stock. In consideration for the CAP Holders exercising their 
conversion rights, CTI has agreed to issue to the CAP Holders approximately 
9.9 million shares of its common stock. The CAP Holders have agreed to be 
investors in the above described Notes Agreement. The closing of the CAP 
Agreement is expected to coincide with, and is conditioned upon, the closing 
of the Notes Agreement.
These securities have not been registered under the Securities Act of 1933, 
as amended, or any state securities laws. The Notes, the common stock 
issuable upon conversion of the Notes and the common stock CTI has agreed to 
issue to the CAP Holders in consideration for the exercising of their 
conversion rights under the 4% Notes and 5.75% Notes may not be offered or 
sold in the United States absent registration or an applicable exemption 
from the registration requirements of the Securities Act of 1933, as 
amended, and any applicable state laws.
This announcement is neither an offer to sell nor a solicitation of an offer 
to buy any of these securities. No offer, solicitation or sale will be made 
in any jurisdiction in which such offer, solicitation or sale is unlawful.
For more information, refer to the following table detailing certain 
transaction data.
Certain Transaction Data
Retirement of $38.4 million of existing convertible debt
Annual Aggregate Maturity Conversion Shares to New
coupon amount of date price per be issued issued
old debt share upon restricted
being conversion shares
retired
5.75% $18.53
million 2008 $10.00 1,853,000
4.00% $19.85
million 2010 $13.50 1,470,371
Total $38.38
million 3,323,371 9,877,932
Issuance of $82.0 million of new convertible debt
Annual Aggregate amount Maturity Conversion Shares issuable
coupon of new debt date price per upon conversion
share
6.75% $82.0 million (1) 2010 $2.63 31,178,707
(1) $24.6 million of this debt is subject to mandatory redemption by the 
Company on April 30, 2006 at the option of the holders. Any such mandatory 
redemption will exclude accrued and unpaid interest.
This press release includes forward-looking statements that involve a number 
of risks and uncertainties, the outcome of which could materially and/or 
adversely affect actual future results. The risks and uncertainties include 
the risk that the above described transaction will not close as a result of 
the failure to meet closing conditions, investors may breach or withdraw 
their commitment, and until closed there is no assurance that it will close 
or what the total amount may be, and other risk factors listed or described 
from time to time in the Company's filings with the Securities and Exchange 
Commission including, without limitation, the Company's most recent filings 
on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly 
disclaims any such obligation to) update or alter its forward- looking 
statements whether as a result of new information, future events, or 
otherwise. 

 Cell Therapeutics, Inc. Announces $82 Million in Convertible
ahi ahi ahi...
      Cell T.: lancia convertibile da 82 mln usd al 2010 -2-
      Cell T. ha inoltre annunciato di aver siglato un accordo Cap 
(Conversion And Placement) con due investitori istituzionali qualificati su 
circa 38,38 mln usd di titoli convertibili al 5,75% in scadenza al 2008 ed 
al 4% in scadenza al 2010. Le controparti hanno accettato di convertire i 
propri titoli in circa 3,3 mln azioni di Cell T., mentre la societa' quotata 
a Milano ed al Nasdaq ha accettato di emettere ai due soggetti circa 9,9 mln 
di proprie azioni. red/bac (END) Dow Jones Newswires Copyright (c) 2005 
MF-Dow

 Through Equity Exchange
si va(andate) per area 085-1.2$


quando i soldi servono servono ... per far salire le quotazioni  il tempo
non manca di certo..

E' bello nella vita essere ingenui sognatori come te, ma in borsa non  è 
proficuo.
Iconvertibili sono un male per le societa che ne fanno uso,è un'ultima 
spiaggia..
-
"Harry Plotter ®"


 -
non direi che sia un male, un male sarebbe stato non poter mostrare al mondo
ed alla FDA in particolare il vero valore dello Xyotax o del Pixandrone solo
perchč a causa dello scarso contante in cassa non si sarebbe potuto
terminare i Trials.
Insomma un mancato fallimento a poca distanza del traguardo č un bene per
l'azienda a mio avviso, per te forse no?

Un nuovo bond "VecchiaParmalat" al 6,75%!!!
Mecojo*i!!!
Saluti cometemettopronoerbue
apuo